RT Journal Article
T1 EGFR-Based Immunoisolation as a Recovery Target for Low-EpCAM CTC Subpopulation
A1 Vila, Ana
A1 Abal Posada, Miguel
A1 Muinelo Romay, Laura
A1 Rodríguez Abreu, Carlos
A1 Rivas Rey, José
A1 López López, Rafael
A1 Costa, Clotilde
K1 Circulating tumour cells
K1 Metastasis
K1 Micrometastasis
K1 Epithelial Cell Adhesion Molecule (EpCAM)
K1 Primary tumour
AB Circulating tumour cells (CTCs) play a key role in the metastasis process, as they are responsible for micrometastasis and are a valuable tool for monitoring patients in real-time. Moreover, efforts to develop new strategies for CTCs isolation and characterisation, and the translation of CTCs into clinical practice needs to overcome the limitation associated with the sole use of Epithelial Cell Adhesion Molecule (EpCAM) expression to purify this tumour cell subpopulation. CTCs are rare events in the blood of patients and are believed to represent the epithelial population from a primary tumour of epithelial origin, thus EpCAM immunoisolation is considered an appropriate strategy. The controversy stems from the impact that the more aggressive mesenchymal tumour phenotypes might have on the whole CTC population. In this work, we first characterised a panel of cell lines representative of tumour heterogeneity, confirming the existence of tumour cell subpopulations with restricted epithelial features and supporting the limitations of EpCAM-based technologies. We next developed customised polystyrene magnetic beads coated with antibodies to efficiently isolate the phenotypically different subpopulations of CTCs from the peripheral blood mononuclear cells (PBMCs) of patients with metastatic cancer. Besides EpCAM, we propose Epidermal Growth Factor Receptor (EGFR) as an additional isolation marker for efficient CTCs detection.
PB Plos
YR 2016
FD 2016
LK http://hdl.handle.net/10347/22911
UL http://hdl.handle.net/10347/22911
LA eng
NO Vila A, Abal M, Muinelo-Romay L, Rodriguez-Abreu C, Rivas J, López-López R, et al. (2016) EGFR-Based Immunoisolation as a Recovery Target for Low-EpCAM CTC Subpopulation. PLoS ONE 11(10): e0163705. doi:10.1371/journal.pone.0163705
NO This work was supported by Axencia Galega de Innovación (Xunta de Galicia) and InveNNta (Innovation in Nanomedicine), cofinanced by the European Union (EU) through the Operational Programme for Cross-border Cooperation: Spain-Portugal (POCTEP 2007-2013), and European Regional Development Fund (ERDF)
DS Minerva
RD 22 abr 2026